{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-009222","form_type":"8-K","ticker":"IVF","cik":"0001417926","company_name":"INVO Fertility, Inc.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.853747+00:00","generated_at":"2026-06-17T12:32:44.657348+00:00","sec_items":["1.01","2.04","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"INVO Bioscience closes $3M offering with warrants exercisable at $0.63","bullets":["Gross proceeds of ~$3.0M from sale of 3,680,000 shares (or pre-funded warrants) and 5,520,000 warrants.","Warrants exercisable immediately at $0.63/share, expire in eight years.","Net proceeds to repay up to $500K convertible debentures (at 105%) and fund acquisition down payment for Wisconsin Facility Institute.","Placement agent Maxim Group LLC received 5.0% fee and warrants for 147,200 shares at $0.8965.","Officers and directors subject to 180-day lock-up on equity transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-009222","json":"https://secwatch.observer/filing/0001493152-23-009222.json","markdown":"https://secwatch.observer/filing/0001493152-23-009222.md","text":"https://secwatch.observer/filing/0001493152-23-009222.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223009222/0001493152-23-009222-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223009222/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T12:32:44.657348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"10632c41cef6b3318ed809abbce871686536986c","claim":"INVO Fertility, Inc. entered into Placement Agency Agreement with Maxim Group LLC (effective 2023-03-23).","evidence_excerpt":"Also in connection with the offering, on March 23, 2023, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223009222/0001493152-23-009222-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Maxim Group LLC"},{"label":"Effective","value":"2023-03-23"}],"fact_type":"material_agreement"},{"claim_id":"59816ded278c102cb924bf9231b5f342da5d804b","claim":"INVO Fertility, Inc. entered into Purchase Agreement with certain institutional investors (effective 2023-03-23).","evidence_excerpt":"On March 23, 2023, INVO Bioscience, Inc., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223009222/0001493152-23-009222-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Effective","value":"2023-03-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}